Gilead Sciences Price to Book Ratio 2006-2021 | GILD

Historical price to book ratio values for Gilead Sciences (GILD) over the last 10 years. The current price to book ratio for Gilead Sciences as of October 22, 2021 is 4.28.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Gilead Sciences Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 67.24 4.28
2021-06-30 68.17 $15.72 4.34
2021-03-31 63.33 $15.12 4.19
2020-12-31 56.43 $14.53 3.88
2020-09-30 60.52 $13.94 4.34
2020-06-30 72.94 $14.47 5.04
2020-03-31 70.22 $17.69 3.97
2019-12-31 60.43 $17.89 3.38
2019-09-30 58.40 $16.38 3.57
2019-06-30 61.67 $17.96 3.43
2019-03-31 58.79 $17.34 3.39
2018-12-31 56.02 $16.80 3.34
2018-09-30 68.57 $17.78 3.86
2018-06-30 62.43 $16.77 3.72
2018-03-31 65.91 $15.89 4.15
2017-12-31 62.19 $15.67 3.97
2017-09-30 69.84 $19.32 3.61
2017-06-30 60.63 $17.68 3.43
2017-03-31 57.72 $16.00 3.61
2016-12-31 60.39 $14.78 4.09
2016-09-30 66.31 $13.13 5.05
2016-06-30 69.49 $12.11 5.74
2016-03-31 76.10 $10.40 7.32
2015-12-31 83.43 $13.44 6.21
2015-09-30 80.40 $12.38 6.49
2015-06-30 95.74 $11.29 8.48
2015-03-31 79.95 $11.91 6.71
2014-12-31 76.80 $10.55 7.28
2014-09-30 86.73 $9.16 9.47
2014-06-30 67.55 $10.77 6.27
2014-03-31 57.73 $8.91 6.48
2013-12-31 61.19 $7.66 7.99
2013-09-30 51.22 $7.30 7.02
2013-06-30 41.77 $7.42 5.63
2013-03-31 39.87 $6.82 5.85
2012-12-31 29.92 $6.28 4.76
2012-09-30 27.02 $5.77 4.68
2012-06-30 20.89 $5.35 3.91
2012-03-31 19.90 $4.86 4.10
2011-12-31 16.67 $4.56 3.66
2011-09-30 15.81 $4.12 3.83
2011-06-30 16.87 $4.00 4.22
2011-03-31 17.30 $3.90 4.43
2010-12-31 14.76 $3.82 3.87
2010-09-30 14.51 $3.60 4.02
2010-06-30 13.97 $3.90 3.58
2010-03-31 18.52 $4.16 4.45
2009-12-31 17.63 $3.62 4.88
2009-09-30 18.94 $3.19 5.94
2009-06-30 19.08 $2.94 6.50
2009-03-31 18.87 $2.77 6.82
2008-12-31 20.83 $2.45 8.49
2008-09-30 18.59 $2.26 8.22
2008-06-30 21.57 $2.04 10.55
2008-03-31 20.99 $1.81 11.62
2007-12-31 18.74 $1.86 10.10
2007-09-30 16.65 $1.61 10.37
2007-06-30 15.81 $1.34 11.76
2007-03-31 15.61 $1.28 12.20
2006-12-31 13.23 $0.98 13.44
2006-09-30 14.01 $1.80 7.79
2006-06-30 12.05 $1.75 6.88
2006-03-31 12.67 $1.83 6.92
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $84.306B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76